Detalhe da pesquisa
1.
Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort.
J Urol
; 209(5): 882-889, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36795962
2.
Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
J Urol
; 207(3): 541-550, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34643090
3.
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.
J Urol
; 207(1): 70-76, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34445891
4.
Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer.
World J Urol
; 40(11): 2707-2715, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36169695
5.
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
BJU Int
; 128(1): 79-87, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152179
6.
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
BJU Int
; 127(5): 528-537, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32981193
7.
Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer.
World J Urol
; 39(12): 4345-4354, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34370078
8.
Germline and somatic DNA repair gene alterations in prostate cancer.
Cancer
; 126(13): 2980-2985, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32315455
9.
Utility of Intraprocedural Contrast-Enhanced CT in Ablation of Renal Masses.
AJR Am J Roentgenol
; 214(1): 122-128, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31532258
10.
Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance.
BJU Int
; 124(5): 730-737, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30740876
11.
Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.
Cancer
; 124(9): 1921-1928, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29499075
12.
Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry.
World J Urol
; 35(2): 277-283, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27306686
13.
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
Cancer
; 122(12): 1897-904, 2016 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27019001
14.
15.
Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review.
J Urol
; 193(5): 1525-31, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25444980
16.
Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy.
J Urol
; 193(2): 436-42, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25063493
17.
Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis.
J Urol
; 194(2): 304-308, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25797392
18.
Patient and disease factors affecting the choice and adherence to active surveillance.
Curr Opin Urol
; 25(3): 272-6, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25692724
19.
No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period.
Cancer
; 120(6): 818-23, 2014 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24258693
20.
Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
Urol Oncol
; 42(6): 177.e5-177.e14, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38480079